Crysvita: targeted treatment option for X-linked hypophosphatemia

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 2:11 PM ET. Details in the imprint.

Crysvita is a monoclonal antibody treatment from Kyowa Kirin that is approved in the United States for X-linked hypophosphatemia (XLH) in both children and adults, offering a targeted option that acts directly on the FGF23 pathway rather than only replacing phosphate and vitamin D. The product, which is co-developed and commercialized with Ultragenyx in certain regions, marked the first therapy in the US to specifically address the underlying cause of XLH when it received its initial FDA approval in 2018. For US patients and families navigating this rare, lifelong bone disease, Crysvita has become a cornerstone prescription option prescribed and administered in specialist centers rather than a retail pharmacy product.

What Crysvita does and how it is used in the US

Crysvita (burosumab-twza) is designed to bind and inhibit fibroblast growth factor 23 (FGF23), a hormone that is overactive in XLH and drives chronic phosphate wasting in the kidneys. By blocking excess FGF23, the drug increases renal phosphate reabsorption and raises serum phosphate levels, which in turn supports healthier bone mineralization in children and adults living with XLH. The therapy is given as a subcutaneous injection and is indicated in the US for patients 6 months of age and older with XLH and for adults with tumor-induced osteomalacia (TIO) with tumors that cannot be located or removed, reflecting a broad label across key FGF23-related hypophosphatemic conditions.

According to the US prescribing information, Crysvita dosing is weight-based and administered every two or four weeks depending on age and indication, with serum phosphate monitoring guiding dose adjustments to avoid hyperphosphatemia. In pediatric XLH, doses are typically given every two weeks, whereas adults with XLH or TIO may receive injections every four weeks as a starting schedule. Administration usually takes place in a specialty clinic or infusion center, and the product is supplied as a refrigerated, single-use vial that a healthcare professional prepares immediately before injection. Because XLH is rare and requires long-term management, Crysvita is reimbursed in the US primarily through specialty pharmacy and medical benefit channels, often with prior authorization and patient-support programs coordinated through the manufacturer and partner organizations.

Clinical studies underpinning US approval showed that Crysvita significantly improved serum phosphate levels and radiographic signs of rickets in children with XLH compared with conventional therapy based on oral phosphate and active vitamin D analogs. In pivotal pediatric trials, a majority of treated children reached serum phosphate levels in the normal range and demonstrated improved rickets severity scores over 40 to 64 weeks of treatment compared with control groups receiving conventional therapy. Adult XLH patients on Crysvita experienced improvements in stiffness, walking distance, and physical function scores, along with better serum phosphate control than placebo, supporting its use across the age spectrum. These data, along with its orphan-drug status, have made the medicine a reference option in US guidelines and expert recommendations for XLH management in suitable patients.

From a safety standpoint, the most commonly reported adverse reactions in pediatric XLH studies included injection site reactions, headache, vomiting, fever, and decreased vitamin D levels, while adults more frequently experienced back pain, headache, tooth abscess, and restless leg syndrome. Importantly, the label carries warnings about the risk of hyperphosphatemia and potential ectopic mineralization, including nephrocalcinosis, which underscores why the drug is used with regular monitoring and why conventional oral phosphate and active vitamin D are generally discontinued before starting treatment. For US families comparing options, this risk-benefit profile means Crysvita is typically considered where the goal is to address the underlying phosphate wasting in a structured, physician-managed setting, rather than relying exclusively on older supplementation regimens.

For the US market, Crysvita is distributed as a prescription biologic through specialty pharmacies and institutional channels, with an average wholesale acquisition cost that places it firmly in the high-cost rare disease category. Kyowa Kirin and its US partner promote patient-access programs that may include co-pay assistance, case-management support, and coordination with insurers, reflecting the complexity of reimbursement for orphan biologics in the American healthcare system. While the exact net price varies widely by payer contract and support program, published list-price estimates for similar orphan biologics often run into the hundreds of thousands of US dollars per patient per year, underscoring why conversations with insurers and support services are an integral part of getting started on therapy.

Within Kyowa Kirin’s broader portfolio, Crysvita is one of the company’s key global growth drivers, alongside oncology and immunology products, and it represents a strategic pillar in the firm’s focus on specialty medicines for rare and underserved diseases. For US patients, caregivers, and healthcare providers evaluating options in XLH and related FGF23-mediated conditions, Crysvita offers a targeted, data-backed treatment pathway anchored in specialty care and careful monitoring. Shares of Kyowa Kirin (JP3249600002, ticker 4151) last traded in Tokyo, with the company’s American depositary receipts not listed on a major US exchange as of recent public filings.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.